Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)Key Points: Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next… Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this… Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92)Investment Thesis in Brief If you like numbers, you will like this report. It is a very detailed analysis of the… Antares: Makena Has the Potential to Make a Very Significant Contribution to EPS (ATRS, $0.85. Buy)Investment Thesis The launch of Otrexup has been extremely disappointing in contrast to my high expectations. Medac launched a competitive… Antares: The Stock Price Does Not Reflect the Fundamentals (ATRS, $1.60, Buy)Introduction Antares recently updated its corporate presentation on their website. .There were several slides in the presentation that reinforce my confidence… Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)Introduction to Report One of my assets is also one of my biggest drawbacks. When I am writing on a Company… Comments on Agenus and AntaresSmithOnStocks Mailbox My mailbox comments are brief articles on stocks in which I am involved. These can come from… Comments on Antares, Kite Pharma and Northwest BiotherapeuticsSmithOnStocks Mailbox My mailbox comments are brief articles on stocks in which I am involved. These can come from… Comments on Antares, Agenus, Cytokinetics, Discovery Laboratories and ZS PharmaSmithOnStocks Mailbox Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)Overview Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to… Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)Investment Thesis Antares: Highlights of CEO’s Presentation at Piper Jaffray Conference (ATRS, Buy, $2.46)Overview I tuned in to the Antares presentation at the Piper Jaffrey conference on December 2, 2014 to listen to what… Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)
I project 2015 sales of Otrexup at $22 million; if so, it would be generating profit in the latter half… Antares Pharmaceuticals: An Update on Key Issues (ATRS, Buy, $2.14)Investment Thesis Antares (ATRS) common has been hit with a storm of concerns that has caused the stock to decline from… Antares; My View of How Otrexup and Medac’s New Product Rasuvo May Compete (ATRS, Buy, $2.54)Investors Are Concerned About Rasuvo’s Impact on Otrexup Investors have been concerned about the potential effect on Otrexup if the private… Antares: Although it is Still Early, I Think That Otrexup Launch is Going Very Well (ATRS, Buy, $2.93, Paid subscribers)Investment Thesis The broad based business model of Antares results in its receiving revenues from numerous products that are marketed by… Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)Recent Price Behavior Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and… Antares Marketing Agreement on Otrexup with Leo is a Nice Positive (ATRS, $3.93)Antares is preparing to launch Otrexup for rheumatoid arthritis in the US in late January of 2014 with its own… Antares: Thoughts on the Upcoming Otrexup Launch (ATRS, $3.64)Investment Thesis Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)Investment Overview and Thesis |